Study type: In vitro · Status: Verified against declared source

Expression and Purification of Hybrid LL-37Tα1 Chemical sequence inand Evaluation of Its Immunomodulatory and Anti-inflammatory Activities by LPS Neutralization.

Frontiers in immunology · 2019

Study scale: This study pertains to the new approach for the development of hybrid peptide LL-37Tα1 and its biomedical applications.

Abstract only: Open source record

Product or molecular entity relationships

LL-37: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Not reported in the reviewed source.

Methods

Hybridizing different AMPs is most effective method to obtained hybrid peptide having elevated antibacterial, anti-inflammatory, and less cytotoxic capabilities (28, 29).

Scale or participants

This study pertains to the new approach for the development of hybrid peptide LL-37Tα1 and its biomedical applications.

Key findings

This study pertains to the new approach for the development of hybrid peptide LL-37Tα1 and its biomedical applications.

Limitations and uncertainty

To investigate the effect of LL-37 and LL-37Tα1 peptide on LPS-induced apoptosis, mouse RAW264.7 macrophages were cultured and infected with LPS alone and with LPS plus parental and hybrid peptides for 4, 12, and 24 h.

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.